Neuronasal Inc.  has developed a novel nose to brain route for n-acetylcysteine (NAC) which is patent protected and has been shown to deliver drug to the targeted brain regions in a human pilot trial.

NAC  is an approved drug,  which has shown efficacy in human trials with high IV dosing or mega oral doses in the case of Parkinson’s and MTBI respectively.  These delivery approaches are not acceptable for patient use.

Neuronasal’s unique  Intranasal (IN) delivery method of an FDA approved drug is novel, PATENT PROTECTED  as is the method of measuring the level of drug brain delivery.